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COMPARISON BETWEEN CONTINUOUS AND DISCRETE
DOSES USING ESCALATION WITH OVERDOSE CONTROL
MA´RCIO AUGUSTO DINIZ, MOURAD TIGHIOUART, AND ANDRE´ ROGATKO
Abstract. Although there is an extensive statistical literature showing the
disadvantages of discretizing continuous variables, categorization is a common
practice in clinical research which results in substantial loss of information. A
large collection of methods in cancer phase I clinical trial design establishes
dose of a new agent as a discrete variable. A noteworthy exception is the
Escalation With Overdose Control (EWOC) design, where doses can be defined
either as continuous or as a grid of discrete doses. A Monte Carlo simulation
study was performed to compare the operating characteristics of continuous
and discrete dose EWOC designs. Four equally spaced grids with different
interval lengths were considered. The loss of information was measured by
several operating characteristics easier for clinicians to interpret, in addition
to the usual statistical measures of bias and mean squared error. Based on
the simulations, if there is not enough knowledge about the true MTD value
as commonly happens in phase I clinical trials, continuous dose scheme arises
as an attractive option.
1. Introduction
Measurements of continuous variables are made in all fields of medicine. In med-
ical research such continuous variables are often converted into categorical variables
by grouping values into two or more categories in order to have easier interpreta-
tions.
Cox [11] derived an optimization criteria for discretizing a continuous covariable
and showed that if a variable is normally distributed then categorizing it into six
groups implies a minimum loss of 5.8% of information, when using a quadratic loss
function. The minimum loss is 7.99% for five groups, 11.75% for four groups and
19.02% for three groups. Following the rationale of Cox, Connor [10] found other
criteria and reached similar conclusions based on the asymptotic relative efficiency
of the Cochran-Armitage trend test [2] when a continuous covariable, that is linearly
related to a binary response variable, is discretized. In this way, several authors have
pursued methodologies to provide optimal criteria of discretization for continuous
covariables based on other test statistics. See [21], [32], [18], [27], [20].
On the other hand, extensive statistical literature (see [9], [17], [1], [33], [19],
[16] and [26]) has advised against categorization due the loss of power and preci-
sion of the estimated quantities. In particular, Lagakos [17] studied the effects of
mis-measuring covariables, considering a likelihood test for a logistic model when a
continuous covariable following Normal, Exponential or Uniform distribution, is cat-
egorized. He also evaluated the loss of information when the levels of an ordered cat-
egorical covariable is selected incorrectly considering the Cochran-Armitage trend
test.
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This debate is not different for cancer phase I clinical trials, although with its
peculiarities. Phase I trials represent the first testing of an investigational agent in
humans and act as a point of translation of years of laboratory research into the
clinic. The major objective in phase I trials is to identify a maximum tolerable dose
(MTD) for subsequent studies, whereas the primary goal in phase II and III trials
is treatment efficacy. While phase I trials in other areas of medicine enroll healthy
participants, phase I oncology trials typically enroll patients who have advanced
form of cancer and who have exhausted standard treatment options.
Ideally, from a therapeutic perspective, clinical trials should be designed to max-
imize the number of patients receiving an optimal dose. The fundamental conflict
underlying the design of cancer phase I clinical trials is that increasing the dose
slowly to avoid unacceptable toxic events must be balanced against treating many
patients at suboptimal or nontherapeutic doses. [24]
Traditionally, dose finding has been conducted according to the 3 + 3 principle
and its variants, which was first described by Dixon and Mood [13] and require a
pre-specified set of discrete doses. Although the use of rule-based designs is still
prevailing, model-based designs such as the continual reassessment method (CRM)
introduced by O‘Quigley [22] and Escalation With Overdose Control (EWOC) by
Babb et al. [3] have been gaining popularity in clinical practice. [31]
In these model-based designs, a parametric model is considered to describe the
relationship between the probability of a dose limiting-toxicity (DLT) and the dose
level of the new agent, which can be considered as a continuous or a discrete co-
variable.
Clinical trials using continuous dose [6, 5] are less often performed since clinicians
are used to the up-and-down approach, although intravenous drugs are still more
prevalent than oral drugs [14, 34] and continuous dose does not require to pre-
specified a set of doses which is usually an arbitrary decision.
Following the up-and-down approach, a large collection of methods establishes
the dose of a new agent only as a discrete variable based on a pre-specified set
of doses. However, Hu et al. [15] and Chu et al. [8] pointed out the common
assumption by almost all existing methods that one of the pre-specified doses is the
MTD does not hold in practice since often limited prior information regarding the
dose-toxicity relationship of the experimental drug is available.
A noteworthy exception is the EWOC design where doses can be defined either
as continuous or as a grid of discrete doses. For discrete doses, EWOC still will
consider the same continuous dose algorithm, but a final rounding step is added to
the algorithm.
EWOC was the first dose-finding procedure to directly incorporate the ethical
constraint of minimizing the chance of treating patients at unacceptably high doses.
Its defining property is that the expected proportion of patients treated at doses
above the MTD is equal to a specified value α, the feasibility bound. [28]
The feasibility bound could varying along the trial as discussed by Tighiouart
and Rogatko [29]. The rationale behind this approach is that uncertainty about
the MTD is high at the onset of the trial and a small value of α offers protection
against the possibility of administering dose levels much greater than the MTD.
As the trial progresses, uncertainty about the MTD declines and the likelihood of
selecting a dose level significantly above the MTD become significantly smaller.
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Chu et al. [7] compared the performance of different versions of CRM with EWOC
both constant and varying α.
In this work, a Monte Carlo simulation study to compare the operating charac-
teristics of continuous and discrete dose EWOC designs is presented. The loss of
information will be evaluated using the statistical measures bias and mean squared
error as well as specific measures for phase I clinical trials to quantify safety and
efficacy of the trial.
This article is organized as follows. In Section 2, the EWOC design is briefly
introduced. The simulation study is described in Section 3 and its results are
presented in Section 4 with discussion in Section 5.
2. Escalation with Overdose Control
In this section, the EWOC design is briefly reviewed as Babb et al. [3]. Let
Xmin and Xmax denote the minimum and maximum dose levels available for use in
the trial. Note that the dose given to the first cohort of patients is not necessarily
equal to Xmin but there must be strong evidence that it is a safe dose. While the
maximum dose is not a dose that one would ever use to treat a patient, it is a
boundary that would never be exceeded.
In this way, the minimum and maximum doses are respectively the lower and
upper bound of the support of the MTD γ which is defined by
P (DLT |dose = γ) = θ,(2.1)
such that θ is defined as the proportion of expected patients to experience a medi-
cally unacceptable, dose-limiting toxicity if the MTD γ is administered. The rela-
tionship between toxicity and dose level could be defined as
P (DLT |dose = x) = F (β0 + β1x),(2.2)
where F is a specified distribution function and β0, β1 are unknown parameters
such that β1 > 0. Following (2.1) and (2.2), the MTD will be given by
γ =
F−1(θ)− β0
β1
= Xmin +
F−1(θ) − F−1(ρ0)
β1
,
where ρ0 denotes the probability of a DLT at the initial dose often established as
x1 = Xmin. Using the definition of the MTD and probability of toxicity at initial
dose, one can show that
β0 =
γF−1(ρ0)−XminF
−1(θ)
γ −Xmin
,
β1 =
F−1(θ)− F−1(ρ0)
γ −Xmin
.(2.3)
Denoting by yi the toxicity response (1 for DLT and 0 for no DLT) of the ith
patient. The likelihood of the data Dk = {(xi, yi), u = 1, . . . , k} after observation
of k patients is
L(ρ0, γ|Dk) =
k∏
i=1
F (β0 + β1xi)
yi [1− F (β0 + β1xi)]
1−yi .(2.4)
for (β0, β1) defined as funtions of (ρ0, γ) given in (2.3).
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Prior information is incorporated for (ρ0, γ) such that prior distributions could
be chosen under the restrictions of γ ∈ [Xmin, Xmax] and ρ0 ∈ (0, 1). The natural
choice is a Beta(aρ, bρ) distribution for ρ0 and a re-escaled Beta(aγ , bγ) distribution
for γ, but Tighouart et al. [30] examine a large class of prior distributions which
could be considered.
Finally, the calculation of the posterior distribution for (ρ0, γ) can be evaluated
[25] and implemented using numerical integration and Markov chain Monte Carlo
sampler
pi(ρ0, γ|Dk) = c(Dk)L(ρ0, γ|Dk)pi(ρ0, γ),(2.5)
where c(Dk) is a normalizing constant.
Hence, the k + 1 patient receives the dose given by the α-quantile of the γ
posterior distribution
xk = Π
−1(α|Dk),(2.6)
for α being the probability that the dose selected by EWOC is higher than the
MTD.
There are several suggestions for the choice of the feasibility boundary. Originally
Babb et al. [3] suggested a fixed feasibility boundary α equal to 0.25, denoted by
F(0.25). Babb and Rogatko [4] suggested an increasing feasibility boundary until
to 0.5 with initial α equal 0.25, denoted by I(0.25, 0.05). Rogatko and Tighiouart
[23] suggested a similar strategy, but conditionally to the previous patient has no
DLT, denoted by C(0.25, 0.05).
For a discrete set of doses, EWOC is performed using dose as continuous with
an additional step that could either round down xk to the closest dose prioritizing
safety or round to the nearest dose preferring ability to explore the available grid
of doses.
3. Simulation study
Escalation with Overdose Control was applied for continuous dose and discrete
dose which were denoted by dose schemes. The minimum and maximum doses were
standardized as Xmin = 0 and Xmax = 1. Considering the discrete dose scheme,
four equally spaced grids with different interval lengths between two doses given by
0.05, 0.10, 0.2 and 0.25 such that each grid will be indicated by its interval length.
The grid 0.05 has 21 doses, the grid 0.10 has 11 doses, the grid 0.20 has 6 doses
and the grid 0.25 has 5 doses.
The DLT proportion threshold was established equal to 0.33 such that four
true values of MTD = {0.2, 0.4, 0.6, 0.8} and four true distributions Logistic(0, 1),
Normal(0, 2), Skew-Normal(0, 2, 3) and Skew-Normal(0, 2, -3) were considered.
Three different sample sizes n = 20, 40, 60 with cohorts of one patient were treated.
In the discrete dose scheme, rounding nearest approach was applied and skipping
doses was not allowed.
A Monte Carlo study was performed considering 1000 replicates for each study
design. The classical statistical measures of bias and mean square error (MSE)
were evaluated as well as operating characteristics more interpretable for clinicians:
average DLT rate, percentage of trials which DLT proportion is outside the target
rate interval θ ± 0.10, the percentage of trials with the estimated MTD within the
optimal MTD interval defined as True MTD ± 0.15× True MTD and the optimal
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toxicity interval defined as θ ± 0.10, the percentage of patients receiving optimal
doses defined by the optimal MTD and toxicity intervals.
From the perspective of a patient participating in a dose finding trial, the best
design is the one with the highest proportion of patients receiving optimal doses
such that optimal doses could be defined in different perspectives. In this way, it is
worth to characterize the discrete dose schemes based on the number of possibles
doses could be considered as optimal doses based on the optimal MTD interval
which can be seen in Table 1.
True MTD Optimal Interval
dose scheme
D0.05 D0.10 D0.20 D0.25
0.2 (0.17 ; 0.23) 4.8 (1) 9.1 (1) 16.7 (1) 0.0 (0)
0.4 (0.34 ; 0.46) 14.3 (3) 9.1 (1) 16.7 (1) 20.0 (1)
0.6 (0.51 ; 0.69) 14.3 (3) 9.1 (1) 16.7 (1) 0.0 (0)
0.8 (0.68 ; 0.92) 23.8 (5) 27.3 (3) 16.7 (1) 20.0 (1)
Table 1. Percentage (Number) of doses relative to each discrete
dose scheme which can be considered as an optimal dose based on
the optimal MTD interval (True MTD± 0.15× True MTD)
Dose schemes D0.05 and D0.10 for some true MTD values present more than one
dose which can be considered as an optimal dose. Furthermore, the dose scheme
D0.25 does not contain any possible dose which could be considered as an optimal
dose for the true MTD values 0.2 and 0.6.
On the other hand, slight differences from the true MTD could imply notable
differences on toxicity, therefore optimal doses can also be defined based on the
optimal toxicity interval. The dose schemes are evaluated based on the optimal
toxicity interval in Table 2. All discrete dose schemes contains at least one optimal
dose on the perspective of the optimal toxicity interval such that all discrete dose
schemes contain at least 30% of the doses which can be considered as optimal doses
when the true MTD is 0.6 and 0.8. If the toxicity optimal interval is defined as
θ± 0.05 instead of θ± 0.10, then the results for optimal toxicity interval are similar
to optimal MTD interval.
True MTD
dose scheme
D0.05 D0.10 D0.20 D0.25
0.2 14.3 (3) 9.1 (1) 16.7 (1) 20.0 (1)
0.4 23.8 (5) 27.3 (3) 16.7 (1) 20.0 (1)
0.6 38.1 (8) 36.4 (4) 33.3 (2) 40.0 (2)
0.8 47.6 (10) 45.5 (5) 50.0 (3) 40.0 (2)
Table 2. Percentage (Number) of doses relative to each discrete
dose scheme which can be considered as an optimal dose based on
the optimal toxicity interval (θ ± 0.10)
All the simulations were performed using the R-package EWOC available at
GitHub [12]. The following section will address several aspects about continuous
and discrete dose schemes under different aspects of EWOC.
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4. Results
The working model is the Logistic model. The feasibility strategy C(0.05, 0.05)
was fixed. There are 12 (4 true MTD × 3 sample sizes) simulations for each dose
scheme and true model. The operating characteristics are presented in Figures 1 -
4 using median, 25% and 75% quantiles.
Figure 1 shows results of the relative loss for the bias and the mean square error
of the four discrete dose schemes. There is no significant differences among the dose
schemes for bias, but there is a increasing pattern for the mean square error as the
number of doses in the dose scheme decreases.
The relative loss of information for the average DLT proportion and the percent-
age of trials which DLT proportion is outside the target rate interval are presented
in Figure 2. All discrete dose schemes are safer or equivalent to the continuous dose.
However, the percentage of trials which DLT proportion is outside the target rate
increases as the number of doses decreases indicating the lack of ability to explore
the possible doses.
Figure 3 presents the relative loss for the percentage of trials which the estimated
MTD is inside the optimal MTD interval and the average percentage of patients
receiving optimal MTD doses. The dose scheme D0.25 presents remarkably worse
performance, as expected based on Table 1, than the continuous dose and the
other discrete dose schemes which contain the true MTD value for both operating
characteristics. On the contrary, the dose scheme D0.2 surpasses the continuous
dose since this dose scheme is the smallest set which always contains the true MTD
among the discrete dose schemes considered.
The estimated MTD is inside the optimal toxicity interval and the average per-
centage of patients receiving optimal toxicity doses are presented in Figure 4. Re-
sults are similar to Figure 3, but less extent since former operating characteristics
are less stringent as showed in Table 2.
5. Discussion
Escalation with Overdose Control can be implemented based on either a contin-
uous or a discrete dose scheme allowing the comparison between them. This work
compared such dose schemes considering several misspecified scenarios and samples
size with a conditional feasibility strategy. The dose schemes were evaluated based
on the most common statistical, safety and efficiency measures of five doses schemes
corresponding to a continuous dose and four different pre-specified set of doses with
different increment sizes.
The discretization of the continuous doses increases the variance of the MTD
estimate and decreases the ability to explore the dose range. Moreover, the contin-
uous dose scheme is favored based on the percentage of trials with the estimated
MTD inside the optimal MTD and toxicity (defined as θ± 0.05) intervals as well as
the average percentage of patients receiving doses inside the optimal MTD and tox-
icity (defined as θ± 0.05) intervals when the discrete dose scheme does not contain
the true MTD or the pre-specified set of doses contains a large number of doses.
Phase I clinical trials usually are performed with 5 or 6 doses chosen based
on arbitrary criteria. Recent works [15], [8] presented ideas to add new doses
along the trial into the pre-specified discrete dose scheme. If there is not enough
knowledge about the true MTD value as commonly happens in phase I clinical
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trials, continuous dose scheme arises as an attractive and more genuine option to
avoid protocol amendments.
Figure 1. Bias and Square root of MSE as a function of true
distribution and dose scheme
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Figure 2. DLT Average and Percentage of trials such that the
observed DLT probability is outside the interval [θ − 0.1; θ + 0.1]
as a function of true distribution and dose scheme
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Figure 3. Percentage of trials with the estimated MTD inside the
MTD optimal interval and average percentage of patients receiving
doses inside the optimal MTD as a function of true distribution and
dose scheme
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Figure 4. Percentage of trials with the estimated MTD inside the
toxicity optimal interval and average percentage of patients receiv-
ing doses inside the optimal MTD as a function of true distribution
and dose scheme
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